Biogen to submit Spinraza to NICE for STA

Biogen Inc. (NASDAQ:BIIB) said it plans to submit Spinraza nusinersen for a single technology appraisal (STA) by the U.K.'s NICE in March to treat spinal muscular atrophy (SMA) after receiving a formal request by the agency. The company said NICE and NHS England will concurrently develop a managed access agreement for Spinraza. Biogen said that to date all eligible children in the U.K. have been treated under a Biogen-NHS deal where the company provides the drug free of charge.

Biogen expects NICE to make its initial recommendation on the STA in June...